SLDB
Solid Biosciences Inc.
NASDAQ · Healthcare · Biotechnology · US
$6.47
+3.03%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$6.59
From 52W high−41.97%
Volume651243.00
Market cap$693.75M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$6.59
From 52W high
−41.97%
Volume
651243.00
Market cap
$693.75M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.6x
P/E (TTM)
—
RSI (14)
46.6
MomentumView details →
1D Return
+3.03%
YTD Return
+13.24%
SummaryUpdated Jun 1, 2026
Solid Biosciences Inc. (NASDAQ:SLDB) is a clinical-stage biotechnology company founded in 2013 and headquartered in Cambridge, Massachusetts. The company went public in January 2018 through an initial public offering. Solid Biosciences focuses exclusively on developing gene therapies for Duchenne Muscular Dystrophy (DMD), a rare and devastating genetic muscle-wasting disease that primarily affects boys. The company is currently advancing two gene therapy candidates through clinical and preclinical development stages.
Similar companies
Latest newsMore news →
The European Commission granted orphan designation to Solid Biosciences' SGT-212 for the treatment of Friedreich's ataxia.9d agoSolid Biosciences announced that seven abstracts were accepted for poster presentation at the ESGCT 2026 Annual Congress, scheduled for October 27–30 in Hamburg, Germany.15d ago